| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinological Oncology |
Departments of Diabetes, Endocrinology and Metabolism, (R.N., W.B., J.G., J.N.) Medical Oncology (R.E.) and Anatomic Pathology (S.W.), City of Hope National Medical Center, Duarte, California 91010
Address all correspondence and requests for reprints to: Jerry Nadler, M.D., Department of Diabetes and Endocrinology, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, California 91010. E-mail: jnadler{at}smtplink.coh.org
The interaction of growth factors, such as epidermal growth factor (EGF) with their receptors, on breast cancer cells can lead to the hydrolysis of phospholipids and release of fatty acids, such as arachidonic acid, which can be further metabolized by the lipoxygenase (LO) pathway. Several LO products have been shown to stimulate oncogenes and have mitogenic and chemotactic effects. In this study, we have evaluated the regulation of 12-LO activity and expression in breast cancer cells and tissues. Leukocyte-type 12-LO messenger RNA (mRNA) expression was studied by a specific RT-PCR method in matched, normal, uninvolved and cancer-involved breast tissue RNA samples from six patients. In each of these six patients, the cancer-involved section showed a much higher level of 12-LO mRNA than the corresponding normal section. 12-LO mRNA levels also were greater in two breast cancer cell lines, MCF-7 and COH-BR1, compared with the nontumorigenic breast epithelial cell line, MCF-10F. The growth of the MCF-7 cells was significantly inhibited by two specific LO blockers but not by a cyclooxygenase blocker. Treatment of serum-starved MCF-7 cells with EGF for 4 h led to a dose-dependent increase in the formation of the 12-LO product, 12-hydroxyeicosatetraenoic acid. EGF treatment also increased the levels of the leukocyte-type 12-LO protein expression at 24 h. These results suggest that activation of the 12-LO pathway may play a key role in basal and EGF-induced breast cancer cell growth.
This article has been cited by other articles:
![]() |
R. Castilla, M. Gadaleta, A. F. Castillo, A. Duarte, I. Neuman, C. Paz, F. Cornejo Maciel, and E. J. Podesta New Enzymes Involved in the Mechanism of Action of Epidermal Growth Factor in a Clonal Strain of Leydig Tumor Cells Endocrinology, July 1, 2008; 149(7): 3743 - 3752. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. R. Preston, N. S. Hill, R. R. Warburton, and B. L. Fanburg Role of 12-lipoxygenase in hypoxia-induced rat pulmonary artery smooth muscle cell proliferation Am J Physiol Lung Cell Mol Physiol, February 1, 2006; 290(2): L367 - L374. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Nony, S. B. Kennett, W. C. Glasgow, K. Olden, and J. D. Roberts 15(S)-Lipoxygenase-2 Mediates Arachidonic Acid-stimulated Adhesion of Human Breast Carcinoma Cells through the Activation of TAK1, MKK6, and p38 MAPK J. Biol. Chem., September 9, 2005; 280(36): 31413 - 31419. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. P. Pidgeon, K. Tang, Y. L. Cai, E. Piasentin, and K. V. Honn Overexpression of Platelet-type 12-Lipoxygenase Promotes Tumor Cell Survival by Enhancing {alpha}v{beta}3 and {alpha}v{beta}5 Integrin Expression Cancer Res., July 15, 2003; 63(14): 4258 - 4267. [Abstract] [Full Text] [PDF] |
||||
![]() |
Graham. P. Pidgeon, M. Kandouz, A. Meram, and K. V. Honn Mechanisms Controlling Cell Cycle Arrest and Induction of Apoptosis after 12-Lipoxygenase Inhibition in Prostate Cancer Cells Cancer Res., May 1, 2002; 62(9): 2721 - 2727. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. C. Y. Wong, W. P. Wang, C. H. Cho, X. M. Fan, M. C. M. Lin, H. F. Kung, and S. K. Lam 12-Lipoxygenase inhibition induced apoptosis in human gastric cancer cells Carcinogenesis, September 1, 2001; 22(9): 1349 - 1354. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Williams and D. H. Phillips Mammary Expression of Xenobiotic Metabolizing Enzymes and Their Potential Role in Breast Cancer Cancer Res., September 1, 2000; 60(17): 4667 - 4677. [Abstract] [Full Text] |
||||
![]() |
V. E. Steele, C. A. Holmes, E. T. Hawk, L. Kopelovich, R. A. Lubet, J. A. Crowell, C. C. Sigman, and G. J. Kelloff Lipoxygenase Inhibitors as Potential Cancer Chemopreventives Cancer Epidemiol. Biomarkers Prev., May 1, 1999; 8(5): 467 - 483. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |